Physician profile
Daniel Y Reuben
NPI 1619979416
$3,063.64
in general payments reported to CMS, 2019-2025
39 companies · $2,591 in 2025
The $2,591 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $472 · 2025: $2,591.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $1,950 · Food and Beverage: $1,114.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $1,950.00 |
| Food and Beverage | $1,113.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beone Medicines USA, INC. | $1,981.19 | 2025 | Tevimbra |
| Array Biopharma INC | $95.52 | 2024-2025 | Mektovi, Braftovi, Tukysa |
| Novartis Pharmaceuticals Corporation | $86.46 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $71.82 | 2024 | Keytruda, Welireg |
| Rigel Pharmaceuticals, INC. | $56.29 | 2024-2025 | Rezlidhia, Tavalisse, Gavreto |
| Astellas Pharma US INC | $50.75 | 2024 | Padcev, Vyloy |
| Adc Therapeutics America, INC. | $49.41 | 2024-2025 | |
| Glaxosmithkline, LLC. | $46.75 | 2024-2025 | Ojjaara, Jemperli, Zejula |
| Pfizer INC. | $46.56 | 2025 | |
| Sobi, INC | $44.85 | 2024-2025 | |
| Servier Pharmaceuticals LLC | $44.44 | 2024 | |
| Genentech USA, INC. | $44.24 | 2025 | Tecentriq, Tecentriq Hybreza, Alecensa |
| Abbvie INC. | $39.93 | 2025 | |
| Exelixis INC. | $34.50 | 2025 | Cabometyx |
| Legend Biotech USA INC. | $32.80 | 2024-2025 | Carvykti |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $32.71 | 2025 | |
| Jazz Pharmaceuticals INC. | $31.67 | 2024 | |
| Beigene USA, INC. | $28.22 | 2025 | Brukinsa |
| Janssen Biotech, INC. | $26.62 | 2024 | Rybrevant |
| Pharmacosmos Therapeutics INC. | $26.59 | 2025 | Monoferric |
| Sumitomo Pharma America, INC. | $25.46 | 2025 | Orgovyx |
| Alexion Pharmaceuticals, INC. | $21.03 | 2025 | Ultomiris |
| Coherus Oncology, INC. | $20.73 | 2024 | |
| Geron Corporation | $19.92 | 2025 | Rytelo |
| Taiho Oncology, INC. | $19.85 | 2025 | Inqovi, Lonsurf |
| Astrazeneca Pharmaceuticals LP | $19.83 | 2025 | Enhertu |
| Bayer Healthcare Pharmaceuticals INC. | $19.32 | 2025 | |
| Ipsen Biopharmaceuticals, INC | $15.77 | 2025 | Onivyde |
| Regeneron Healthcare Solutions, INC. | $15.41 | 2025 | Libtayo |
| Celgene Corporation | $15.00 | 2024 | Opdualag |
9 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Reuben listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.